Nuwellis (NASDAQ:NUWE) Releases Earnings Results, Misses Estimates By $1.09 EPS

Nuwellis (NASDAQ:NUWE) released its quarterly earnings data on Tuesday. The company reported ($2.09) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($1.09), Zacks reports. Nuwellis had a negative net margin of 211.86% and a negative return on equity of 6,094.26%.

Here are the key takeaways from Nuwellis’ conference call:

• Nuwellis said Q1 revenue rose 26% year over year to $2.4 million, driven by stronger console sales and a 15% increase in circuit sales as more patients were treated with Aquadex therapy.
• Gross margin improved to 70.1%, which management attributed to better pricing, product mix, and the shift to contract manufacturing.
• The company completed the Rendiatech acquisition to expand its cardiorenal platform, with management saying the technology could add bedside kidney-function monitoring and is targeted for a U.S. launch in 2027.
• Pediatrics is becoming a major growth driver, now representing about 50% of U.S. revenue, with the footprint expanding to 47 centers including six top children’s hospitals.
• Despite improving revenue and margins, operating expenses rose to about $6 million and the company reported a net loss of approximately $4.3 million, while ending the quarter with $2.2 million of cash and no debt.

Nuwellis Stock Performance

Shares of NASDAQ NUWE traded down $0.03 during mid-day trading on Tuesday, hitting $1.02. The stock had a trading volume of 27,197 shares, compared to its average volume of 1,474,640. Nuwellis has a 1 year low of $0.96 and a 1 year high of $43.18. The business has a 50 day moving average price of $1.18 and a two-hundred day moving average price of $1.98. The firm has a market cap of $2.50 million, a P/E ratio of -0.01 and a beta of 0.25.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Nuwellis in a research note on Friday, March 27th. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold”.

Nuwellis Company Profile

Nuwellis (NASDAQ:NUWE) is a medical technology company focused on developing therapies and devices to manage fluid overload in patients with cardiorenal and cardiovascular conditions. The company’s core business revolves around designing, manufacturing and marketing the Aquadex™ FlexFlow® System, a gentle ultrafiltration device intended to remove excess fluid in patients with acute decompensated heart failure, cardiorenal syndrome and other fluid‐overload disorders. By providing an alternative to traditional diuretic therapy, Nuwellis aims to improve patient outcomes and reduce hospital stays.

The Aquadex FlexFlow System operates by drawing blood through a low‐shear filter and returning it to the patient, allowing precise control of fluid removal at the bedside outside of an intensive care setting.